ITRACONAZOLE 50mg. IP

A newer formulation of itraconazole with SUBA drug delivery technology. An innovative antifungal medicine that prevents fungal infections in various parts of the body. A new treatment option that fights life-threatening fungal infections. Exhibits greater bioavailability than conventional itraconazole. (Manjunath Shenoy, 2021) A safe first-line agent for the prevention of invasive fungal infection in those undergoing treatment of hematological malignancies. (Blake Nield, 2019) Exerts antifungal effects by inhibiting the production of ergosterol (a main component of cell membranes of fungi). Provides a rapid improvement and higher complete cure rate (65.38%) than conventional itraconazole (33.33%). (Manjunath Shenoy, 2021) An effective therapy in relieving the symptoms as well as the lesions of dermatophytosis. (Manjunath Shenoy, 2021) A potent therapeutic choice to effectively tackle dermatophytosis. (Manjunath Shenoy, 2021) Exhibits better and more significant results than conventional itraconazole, even without the use of a topical antifungal. (Manjunath Shenoy, 2021) More effective drug than conventional itraconazole in the treatment of dermatophytosis. (Harshal Mahajan, 2021) Displays statistically significant improvements in all types of dermatophytosis infections like naive, recurrent and chronic infections. (Sunil Ghate, 2021)